Generic Pharmaceutical & API Research Services
Lupin's Generic Pharmaceutical Research team has demonstrated a stellar performance with a record number of ANDA filings in the US and other advanced markets from its global R&D hub in Pune, India. With the commissioning of the new R&D building at Pune, India, Lupin can now boast of one of the most advanced pharmaceutical product development & pilot plant facilities for oral, ophthalmic, dermatology and inhalation product development. This facility will be leading future innovations aimed at creating a highly differentiated global pipeline of complex generics.
Lupin’s generic pipeline is focused on identifying and developing high entry barrier products with complexities linked with the delivery system, device compatibility and clinical trial requirement.
Simultaneously, we continue to bolster our oral solids pipeline in view of upcoming patent expiration as well as market needs thereby providing a balanced mix to the pipeline.